Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA1A | P35348 | 9/20 | 1.00 |
| ▸ | ADRA2A | P08913 | 8/20 | 1.00 |
| ▸ | ADRA2B | P18089 | 8/20 | 1.00 |
| ▸ | ADRA2C | P18825 | 8/20 | 1.00 |
| ▸ | ADRA1D | P25100 | 8/20 | 1.00 |
| ▸ | ADRA1B | P35368 | 8/20 | 1.00 |
| ▸ | MAPT | P10636 | 5/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 1.00 |
| ▸ | MEN1 | O00255 | 4/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 4/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 3/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 3/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 3/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 3/20 | 1.00 |
| ▸ | ABCB1 | P08183 | 2/20 | 1.00 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 2/20 | 1.00 |
| ▸ | TP53 | P04637 | 1/20 | 1.00 |
| ▸ | CHRM2 | P08172 | 1/20 | 1.00 |
| ▸ | HTR1A | P08908 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Niguldipine SCHEMBL245992 | 1.00 | ADRA1A (1.00) | ADRA1AADRA2AADRA2BADRA2CADRA1D | |
| Dexniguldipine SCHEMBL29615752 | 1.00 | ADRA1A (1.00) | ADRA1AADRA2AADRA2BADRA2CADRA1D | |
| Dexniguldipine SCHEMBL724137 | 1.00 | ADRA1A (1.00) | ADRA1AADRA2AADRA2BADRA2CADRA1D | |
| Niguldipine SCHEMBL245993 | 1.00 | ADRA1A (1.00) | ADRA1AADRA2AADRA2BADRA2CADRA1D | |
| Niguldipine SCHEMBL29386264 | 1.00 | ADRA1A (1.00) | ADRA1AADRA2AADRA2BADRA2CADRA1D | |
| Niguldipine SCHEMBL3869443 | 0.99 | ADRA1A (0.98) | ADRA1AADRA2AADRA2BADRA2CADRA1D | |
| Niguldipine SCHEMBL9001404 | 0.99 | ADRA1A (1.00) | ADRA1AADRA2AADRA2BADRA2CADRA1D | |
| Niguldipine SCHEMBL467245 | 0.99 | ADRA1A (1.00) | ADRA1AADRA2AADRA2BADRA2CADRA1D | |
| Dexniguldipine SCHEMBL1228966 | 0.99 | ADRA1A (1.00) | ADRA1AADRA2AADRA2BADRA2CADRA1D | |
| SCHEMBL9386117 | 0.98 | ADRA1A (0.95) | ADRA1AADRA2AADRA2BADRA2CADRA1D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024229271-A1 | NANOPARTICLE-BASED THERANOSTIC PLATFORM FOR DIAGNOSIS AND TREATMENT OF SENESCENCE-RELATED PATHOLOGIES | MEMORIAL SLOAN-KETTERING CANCER CENTER (US) | 2024-11-07 | — | — | WO | claimed |
| EP-4058010-A1 | USE OF MAST CELL STABILIZER FOR THE TREATMENT OF HEART FAILURE WITH PRESERVED EJECTION FRACTION | Institut National de la Santé et de la Recherche Médicale (INSERM) (FR) | 2022-09-21 | — | — | EP | claimed |
| US-12599615-B2 | Use of carotenoids in the treatment of senescence-related diseases | GAT THERAPEUTICS, S.L. (ES) | 2026-04-14 | — | — | US | disclosed |
| CN-112804996-B | Use of carotenoids in the treatment of aging-related diseases | 加特治疗有限公司 | 2025-01-14 | — | — | CN | disclosed |
| EP-3485881-B1 | PERMANENTLY CHARGED SODIUM AND CALCIUM CHANNEL BLOCKERS AS ANTI-INFLAMMATORY AGENTS | HARVARD COLLEGE (US) | 2024-03-13 | — | — | EP | disclosed |
| EP-3934631-B1 | CAROTENOIDS IN THE TREATMENT OF SENESCENCE-RELATED DISEASES | GAT THERAPEUTICS S L (ES) | 2024-01-24 | — | — | EP | disclosed |
| EP-4218746-A1 | USE OF CAROTENOIDS IN THE TREATMENT OF SENESCENCE-RELATED DISEASES | Gat Therapeutics S.L. (ES) | 2023-08-02 | — | — | EP | disclosed |
| US-20230165812-A1 | NOCICEPTOR NEURONS CONTROL CANCER IMMUNOSURVEILLANCE | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2023-06-01 | — | — | US | disclosed |
| EP-4144338-A2 | USE OF CAROTENOIDS IN THE TREATMENT OF SENESCENCE-RELATED DISEASES | ALGAKTIV, S.L. (ES) | 2023-03-08 | — | — | EP | disclosed |
| CN-115715804-A | Use of carotenoids in the treatment of age-related disorders | 阿尔加克蒂夫有限公司 | 2023-02-28 | — | — | CN | disclosed |
| US-20220395515-A1 | USE OF CAROTENOIDS IN THE TREATMENT OF SENESCENCE-RELATED DISEASES | ALGAKTIV, S.L. (ES) | 2022-12-15 | — | — | US | disclosed |
| CN-107106606-B | Neuro-micro-physiological system and method of using the same | 杜雷安教育基金会行政处 | 2022-06-14 | — | — | CN | disclosed |
| US-20220152062-A1 | USE OF CAROTENOIDS IN THE TREATMENT OF SENESCENCE-RELATED DISEASES | GAT THERAPEUTICS, S.L. (ES) | 2022-05-19 | — | — | US | disclosed |
| WO-2022054927-A1 | COMPOSITION FOR AUTOPHAGY ACTIVATION | 国立大学法人大阪大学 | 2022-03-17 | — | — | WO | disclosed |
| WO-2022054926-A1 | AUTOPHAGY ACTIVATING COMPOSITION CONTAINING MORPHOLINE DERIVATIVE AS ACTIVE INGREDIENT | 国立大学法人大阪大学 | 2022-03-17 | — | — | WO | disclosed |
| US-20220047505-A1 | Controlled Absorption Water-Soluble Pharmaceutically Active Organic Compound Formulation for Once-Daily Administration | STI PHARMA, LLC (US) | 2022-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220152062-A1 | USE OF CAROTENOIDS IN THE TREATMENT OF SENESCENCE-RELATED DISEASES | BCL2, BCL2A1, BCL2L1 | ADRA1A 4751/4885ADRA2A 4355/4885ADRA2B 4658/4885 |
| US-20230165812-A1 | NOCICEPTOR NEURONS CONTROL CANCER IMMUNOSURVEILLANCE | OPRL1, MRGPRX1, RAMP1 | ADRA1A 877/4885ADRA2A 907/4885ADRA2B 1012/4885 |
| US-20220395515-A1 | USE OF CAROTENOIDS IN THE TREATMENT OF SENESCENCE-RELATED DISEASES | BCL2, BCL2A1, BCL2L1 | ADRA1A 4751/4885ADRA2A 4355/4885ADRA2B 4658/4885 |
| US-12599615-B2 | Use of carotenoids in the treatment of senescence-related diseases | MCL1, BCLAF1, BCL2A1 | ADRA1A 4194/4885ADRA2A 4395/4885ADRA2B 4518/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.